The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node–positive disease and if drug maker Roche adheres to its promised discount for the drug.
The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node—positive disease and if drug maker Roche adheres to its promised discount for the drug.
NICE’s final appraisal indicates that Roche has offered the National Health Service (NHS) a discount on the drug, which carries a UK list price of £2395 (approximately $3068) per 420-mg vial. That discount, taken together with the cost savings made possible by biosimilar trastuzumab agents that have recently entered the UK market, brings the cost-effectiveness estimate for the therapy per quality-adjusted life-year (QALY) gained to “comfortably below £20,000,” or below approximately $25,627, which is NICE’s typical cost-effectiveness threshold.
The decision is a turn-around from previous appraisals of pertuzumab in early breast cancer; in an appraisal consultation document issued in August 2018, NICE noted that biosimilar trastuzumab would lower the cost of treatment, but said it was concerned that the treatment still might not be cost effective.
The 2018 appraisal said that, while the APHINITY trial showed that pertuzumab improved invasive disease-free survival, improvement was marginal, and there was uncertainty about the estimates of the drug’s effect; NICE also said that Roche’s incremental cost-effectiveness ratios included “optimistic” assumptions about the duration of the treatment’s benefit, and it concluded that pertuzumab could not be recommended for routine use.
In its updated and final appraisal, NICE notes it “considered the current commercial-in-confidence price and biosimilar trastuzumab market share to be most appropriate for decision making,” and used a weighted-average biosimilar trastuzumab discount in its estimates. NICE noted that the biosimilar discounts and the new commercial offer are now sufficient to offset the uncertainty about the estimated QALYs gained, at least for patients with lymph node—positive disease.
Clinical commissioning groups and the NHS are required to comply with the NICE recommendation within 3 months of its publication, and the NICE guidance will be considered for review in another 3 years.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.